Laimei Pharmaceutical (300006.SZ): Alanyl Glutamine Injection Drug Supplement Application Approved

Zhitongcaijing · 11/26 08:01

Zhitong Finance App News, Laimei Pharmaceutical (300006.SZ) issued an announcement. Recently, the company received the “Drug Supplement Application Approval Notice” for alanyl glutamine injections 50ml: 10g and 100ml: 20g with the approval of the State Drug Administration.

According to reports, alanyl glutamine injection is an Ala-Glu dipeptide nutrient solution developed by Fresenius in Germany. The trade name is Dipeptiven. As part of a clinical nutrition plan, this drug is suitable for parenteral nutrition for patients requiring glutamine supplementation, including patients with catabolism and high metabolism.

Up to now, in addition to the company, 20 domestic enterprises have obtained registration certificates for alanyl glutamine injections, of which 15 have passed the consistency evaluation.

According to data from Yao Rongyun, sales of alanyl glutamine injections in the Chinese hospital (full terminal) market in 2021-2023 were 1,601 billion yuan, 1,458 billion yuan, and 1,101 billion yuan, respectively.